Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
AstraZeneca
Moodys
Boehringer Ingelheim
Express Scripts

Last Updated: May 27, 2022

CLINICAL TRIALS PROFILE FOR ANDROGEL


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Androgel

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00112151 ↗ TEAM: Testosterone Supplementation and Exercise in Elderly Men Completed National Institute on Aging (NIA) Phase 2 2005-01-01 The purpose of this study is to evaluate the effects of testosterone supplementation (AndroGel) on body composition, strength, endurance, cognition, and function in older men.
NCT00112151 ↗ TEAM: Testosterone Supplementation and Exercise in Elderly Men Completed University of Colorado, Denver Phase 2 2005-01-01 The purpose of this study is to evaluate the effects of testosterone supplementation (AndroGel) on body composition, strength, endurance, cognition, and function in older men.
NCT00114114 ↗ Dose-Response of Gonadal Steroids and Bone Turnover in Older Men Completed AbbVie N/A 2004-09-01 The purpose of this study is to determine the levels of testosterone and/or estradiol at which changes in bone turnover, body composition, strength, sexual function etc. begin to occur in older men. This information may help determine when to intervene with hormone replacement therapy in aging men.
NCT00114114 ↗ Dose-Response of Gonadal Steroids and Bone Turnover in Older Men Completed AstraZeneca N/A 2004-09-01 The purpose of this study is to determine the levels of testosterone and/or estradiol at which changes in bone turnover, body composition, strength, sexual function etc. begin to occur in older men. This information may help determine when to intervene with hormone replacement therapy in aging men.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Androgel

Condition Name

Condition Name for Androgel
Intervention Trials
Hypogonadism 15
Secondary Hypogonadism 5
Obesity 4
Metabolic Syndrome 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Androgel
Intervention Trials
Hypogonadism 27
Insulin Resistance 5
Diabetes Mellitus, Type 2 4
Diabetes Mellitus 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Androgel

Trials by Country

Trials by Country for Androgel
Location Trials
United States 151
Canada 7
Netherlands 4
France 2
Israel 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Androgel
Location Trials
Texas 13
New York 12
California 11
Washington 9
Florida 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Androgel

Clinical Trial Phase

Clinical Trial Phase for Androgel
Clinical Trial Phase Trials
Phase 4 11
Phase 3 14
Phase 2/Phase 3 1
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Androgel
Clinical Trial Phase Trials
Completed 34
Unknown status 5
Withdrawn 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Androgel

Sponsor Name

Sponsor Name for Androgel
Sponsor Trials
Solvay Pharmaceuticals 11
University of Washington 5
Repros Therapeutics Inc. 5
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Androgel
Sponsor Trials
Other 56
Industry 33
NIH 9
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
AstraZeneca
Express Scripts
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.